Hypertension and Diabetic Kidney Disease -- Commercial Performance of Both ACE Inhibitors and ARBS is Dependent on Renoprotective Benefits Beyond Blood Pressure Control
Posted on: Friday, 23 December 2005, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c30060) has announced the addition of Hypertension and Diabetic Kidney Disease -- Prevalence, Current Treatment and Future Options to their offering.
The increase in diabetic kidney disease is a worldwide problem. Current treatment centers on antihypertensive inhibitors for the renin-angiotensin system and merely retards the decline of renal function. A largely unmet need thus exists for therapies that fully halt disease progression or provide curative benefit.
The prevalence and progression of diabetic nephropathy in the seven major markets is evaluated in this report. The foremost pharmacological strategies for the treatment of diabetic nephropathy are reviewed and the current status of angiotensin II receptor blockade as first line therapy in the treatment of diabetic nephropathy is discussed. An overview is given of the drugs in development for the treatment of diabetic nephropathy.
The necessity for aggressive blood pressure control is undisputed in the medical community, but the therapeutic focus is now extending to end-organ protection as a treatment goal of equal importance to BP reduction. Thus, commercial performance of both ACE inhibitors and ARBs is dependent on renoprotective benefits beyond blood pressure control.
The pipeline for developmental drugs targeting the cause of diabetic kidney disease is dominated by endothelin receptor antagonists and advanced glycosylation end product inhibitors. The commercial potential for successful new agents is substantial as existing therapies do not halt the progression of diabetic nephropathy to end stage renal disease.
Proximal blockade of the renin-angiotensin system (RAS) through renin inhibition offers greater treatment opportunities than distal inhibition via angiotensin II receptor blockade. Recent basic and clinical research supports the strong theoretical appeal of renin inhibition as the most promising pharmacological strategy in the short-to-medium term.
Reasons to Purchase
-- Explore the growing burden of ESRD on healthcare systems through data on the prevalence and progression of diabetic nephropathy
-- Assess the potential of current treatment options in the diabetic nephropathy arena
-- Identify novel R&D compounds in the diabetic nephropathy pipeline
For more information visit http://www.researchandmarkets.com/reports/c30060
Source: Business Wire
Related Articles
- Data Supports Potential Mechanism for Gentium's Defibrotide in Cancer, Diabetic Nephropathy and Veno-Occlusive Disease
- Drugs that Improve Parkinson's Symptoms May Not Slow Disease Progression
- Carnosine As a Protective Factor in Diabetic Nephropathy: Association With a Leucine Repeat of the Carnosinase Gene CNDP1
- Rosiglitazone Improves Glomerular Hyperfiltration, Renal Endothelial Dysfunction, and Microalbuminuria of Incipient Diabetic Nephropathy in Patients
- Speedel Starts Phase III Study of SPP301 in Diabetic Nephropathy
- Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 and Phase 4 Clinical Program of KRX-101 for Treatment of Diabetic Nephropathy
- Diabetic Nephropathy
- Speedel Announces Breakthrough Phase II Data With SPP301 for Treatment of Diabetic Nephropathy
- Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy By the Advanced Glycation End Product Cross-Link Breaker ALT-711 Via a Protein Kinase C-[Alpha] - Dependent Pathway
- FibroGen Announces FG-3019 Improves Kidney Function in a Late-Stage Disease Model of Diabetic Nephropathy
 |
 |
User Comments (0)
RSS Feeds